Loading stock data…
Ardelyx, Inc. (ARDX)
$3.78+0.07 (+1.89%)
Pre-Market$3.86+0.08 (+2.15%)· Last close Sep 4
Ardelyx, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ardelyx, Inc. in the Healthcare sector is trading at $3.78 with a market capitalization of $976M. Wall Street consensus targets $12.90 (10 analysts), implying a +241.3% move over the next 12 months. The stock is currently near its 52-week low of $3.68, remaining 35.4% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +241.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 34) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $120.88M↑ | $94.47M↓ | $125.22M↑ | $110.33M↑ | $97.66M |
| Gross Profit | $115.12M↑ | $89.66M↓ | $114.37M↑ | $106.35M↑ | $85.26M |
| Operating Income | -$12.43M↑ | -$32.79M↓ | $5.10M↑ | $4.67M↑ | -$14.39M |
| Net Income | -$16.72M↑ | -$37.60M↓ | -$407,000↑ | -$969,000↑ | -$19.08M |
Peer Comparison
JNJUNHPFE
Fundamentals
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritabl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$975.95M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.73
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-37.38%
Volume
Today's trading volume
2.98M
Recent News
Ardelyx (ARDX) Cuts Guidance On Payer Hurdles As Fair Value Debate Heats Up
Ardelyx (ARDX) recently cut its 2026 IBSRELA revenue guidance to a range of $350 million to $370 million, down from $410 million to $430 million, citing tougher payer utilization-management hurdles that slowed new patient starts. See our latest analysis for Ardelyx. The guidance cut and lowered expectations for IBSRELA have come alongside a sharp reset in Ardelyx’s share price, with the stock down 23.43% on a 30 day share price return basis and 36.33% on a 1 year total shareholder return...
Ardelyx (ARDX) Q2 2026 Earnings Call Transcript
Record revenue masks payer headwinds forcing IBSRELA guidance cuts.
Ardelyx (ARDX) Is Down 19.7% After Raising IBSRELA Revenue Guidance And Narrowing Losses
In August 2026, Ardelyx, Inc. reported second-quarter 2026 results showing revenue of US$120.88 million versus US$97.66 million a year earlier, with net loss narrowing to US$16.72 million and basic loss per share improving to US$0.07 from US$0.08. Alongside its results, Ardelyx updated full-year 2026 guidance, lifting expected IBSRELA revenue to US$350 million–US$370 million while keeping XPHOZAH revenue guidance steady at US$110 million–US$120 million, giving investors a clearer view of how...
Ardelyx (ARDX) Posts Record Revenue, Is The Stock Still 70% Undervalued?
Ardelyx (ARDX) is back in focus after reporting record Q2 2026 revenue driven by IBSRELA and XPHOZAH, while missing earnings estimates and trimming IBSRELA guidance because of payer related hurdles. See our latest analysis for Ardelyx. Despite the record Q2 revenue, Ardelyx’s recent earnings miss and reduced IBSRELA guidance appear to be weighing on sentiment, with the share price down 9.48% over 30 days and 20.81% year to date, even though the 5 year total shareholder return of 220.39%...
New Strong Sell Stocks for August 7th
ARDX, ARDT and GPRE have been added to the Zacks Rank #5 (Strong Sell) List on August 7th, 2026.